Showing 1781-1790 of 3020 results for "".
- Arcutis’ Roflumilast Cream Could Be “Game Changer” for Plaque Psoriasishttps://practicaldermatology.com/news/arcutis-roflumilast-cream-could-be-game-changer-for-plaque-psoriasis/2460467/Arcutis Biotherapeutics, Inc.’s Roflumilast cream (ARQ-151) produced significant improvements in patients with plaque psoriasis in as early as two weeks, according to a results from a phase 2b trial published in The New E
- Mount Sinai Researcher Receives NIH Grant to Study Immune Responses of Patients With Inflammatory Skin Diseases in the Setting of COVID-19https://practicaldermatology.com/news/mount-sinai-researcher-receives-nih-grant-to-study-immune-responses-of-patients-with-inflammatory-skin-diseases-in-the-setting-of-covid-19/2460458/Patients with moderate to severe atopic dermatitis who take a biologic treatment such as dupilumab seem to be protected from developing serious complications of COVID-19 and are also less likely to be hospitalized due to complications. Now, researchers from the Icahn School of Medicine
- AAD Survey: Parents Get the Importance of Sunscreen for their Kidshttps://practicaldermatology.com/news/aad-survey-parents-get-the-importance-of-sunscreen-for-their-kids/2460433/Fully 74 percent of parents today worry about sun protection more with their children than their parents did with them, and 90 percent of parents believe it’s important to teach their children healthy habits now so they will keep them when they are adults, finds a new survey from the Americ
- Global Challenge Addresses Stigma and Bullying Associated with ADhttps://practicaldermatology.com/news/global-challenge-addresses-stigma-and-bullying-associated-with-ad/2460429/
- Galderma: Patients Treated with Dysport Achieved High Levels of Satisfaction and Natural-Looking Results with Two Treatments Per Yearhttps://practicaldermatology.com/news/galderma-patients-treated-with-dysport-achieved-high-levels-of-satisfaction-and-natural-looking-results-with-two-treatments-per-year/2460391/Topline results of DREAM (Dysport Real-world Evaluation and Measured satisfaction study), a clinical study of Dysport (abobotulinumtoxinA) for injection, showed that 95 percent of patients treated with Dysport achieved high levels of satisfaction with two treat
- NEA Announces 2020 Eczema Research Grant Cycle Openinghttps://practicaldermatology.com/news/nea-announces-2020-eczema-research-grant-cycle-opening/2460387/The
- Cynosure Names David Long Global Chief Financial Officerhttps://practicaldermatology.com/news/cynosure-names-david-long-global-chief-financial-officer/2460343/David Long is Cynosure’s new Chief Financial Officer, effective immediately. Until recently, Long served as CFO at Corindus Vascular Robotics, Inc., where he brought the company public and, ultimately, navigated its strategic sale to Siemens.
- HHS OCR: New HIPAA Guidance to Support e-Consultshttps://practicaldermatology.com/news/hhs-ocr-new-hipaa-guidance-to-support-e-consults/2460309/Practices that haven’t contracted with a telehealth platform may still be able to provide virtual consults using standard telecommunications technologies throughout the COVID-19 pandemic. The Office for Civil Rights (OCR) at the Department of Health and Human Services (HHS)
- NEA/PeDRA Offer New Childhood Eczema Challenge Granthttps://practicaldermatology.com/news/neapedra-offer-new-childhood-eczema-challenge-grant/2460298/The
- MyHealthTeams, Global Vitiligo Foundation Team Up to Create New Social Networkhttps://practicaldermatology.com/news/myhealthteams-global-vitiligo-foundation-team-up-to-create-new-social-network/2460293/